{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to no responders","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"20.4","value":"1"},{"comment":"Not estimable due to no responders","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Not estimable due to no responders","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG004","lowerLimit":"0.4","upperLimit":"57.9","value":"1"},{"comment":"Not estimable due to no responders","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants (responders) who achieved disease-specific complete response (CR) or partial response (PR) after treatment. For response assessment of myelofibrosis during both Stage 1 and Stage 2, the International Working Group-Myeloproliferative Neoplasms Research and Treatment and European LeukemiaNet (IWG-MRT/ELN 2013) criteria were used. For chronic myelomonocytic leukemia, during both Stage 1 and Stage 2, the International Working Group 2006 response criteria for myelodysplastic syndromes (IWG MDS 2006) were used for response assessment while the Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) 2015 criteria were used for response assessment during Stage 3A.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment-naive participants with myelofibrosis treated with tagraxofusp 12 µg/kg/day.","id":"OG000","title":"Stages 1-2: Tagraxofusp 12 µg/kg/Day - Treatment Naive - Myelofibrosis"},{"description":"Relapsed/refractory participants with myelofibrosis treated with tagraxofusp 12 µg/kg/day.","id":"OG001","title":"Stages 1-2: Tagraxofusp 12 µg/kg/Day - Relapsed/Refractory - Myelofibrosis"},{"description":"Treatment-naive participants with chronic myelomonocytic leukemia treated with tagraxofusp 12 µg/kg/day.","id":"OG002","title":"Stages 1-2: Tagraxofusp 12 µg/kg/Day - Treatment Naive - Chronic Myelomonocytic Leukemia"},{"description":"Relapsed/refractory participants with chronic myelomonocytic leukemia treated with tagraxofusp 12 µg/kg/day.","id":"OG003","title":"Stages 1-2: Tagraxofusp 12 µg/kg/Day - Relapsed/Refractory - Chronic Myelomonocytic Leukemia"},{"description":"Treatment-naive participants with chronic myelomonocytic leukemia treated with tagraxofusp 12 µg/kg/day","id":"OG004","title":"Stage 3A: Tagraxofusp 12 µg/kg/Day - Treatment Naive - Chronic Myelomonocytic Leukemia"},{"description":"Relapsed/refractory participants with chronic myelomonocytic leukemia treated with tagraxofusp 12 µg/kg/day.","id":"OG005","title":"Stage 3A: Tagraxofusp 12 µg/kg/Day - Relapsed/Refractory - Chronic Myelomonocytic"}],"paramType":"NUMBER","populationDescription":"Modified Intent-to-Treat (mITT): Any participant who received at least 1 dose of study intervention and was evaluable for efficacy assessment. Presentation of reporting groups based upon shared criteria used for response assessment and prior treatment history (previously untreated \\[treatment naive\\]; previously treated \\[relapsed/refractory\\]). Here, 'Overall Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"1145 days","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"participants"}